Detalhe da pesquisa
1.
Low dose interleukin-2 selectively expands circulating regulatory T cells but fails to promote liver allograft tolerance in humans.
J Hepatol
; 78(1): 153-164, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36087863
2.
Tracking immunodynamics by identification of S-G2/M-phase T cells in human peripheral blood.
J Autoimmun
; 112: 102466, 2020 08.
Artigo
Inglês
| MEDLINE | ID: mdl-32414606
3.
A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding.
J Immunol
; 198(1): 528-537, 2017 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27881707
4.
Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial.
PLoS Med
; 13(10): e1002139, 2016 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-27727279
5.
Correction: A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding.
J Immunol
; 199(5): 1943, 2017 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28827388
6.
Chronic Immune Activation in Systemic Lupus Erythematosus and the Autoimmune PTPN22 Trp620 Risk Allele Drive the Expansion of FOXP3+ Regulatory T Cells and PD-1 Expression.
Front Immunol
; 10: 2606, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-31781109